biotech / news / / TNW
STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials.
STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human clinical trials.
KEY POINTS
- In Phase 1, STC-15 showed durable tumour regression across multiple sarcoma subtypes and dose levels.
- STORM Therapeutics raised $56 million in Series C funding entirely from existing investors, including Pfizer Ventures.
- A Phase 2 monotherapy trial of STC-15 has dosed its first patient and aims for accelerated regulatory approval.
- STC-15 is also being tested in combination with toripalimab across multiple other cancer types.
COMPANIES
Summarized by Newsio from TNW. How we summarize →